Evaluation of clinical and paraclinical findings in patients with reactive arthritis caused by giardiasis: A systematic review

Mahdavi, J.; Motavallihaghi, Seyedmousa; Ghasemikhah, Reza

doi:10.1016/j.semarthrit.2022.152094

Cited by 2 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Giardiasis is an intestinal infection caused by the protozoa Giardia lamblia and generally could be reveal in compromised host including HIV and immunosuppressed rheumatic disease patients. It often presents with flatulence, watery diarrhea, and extra‐intestinal manifestation including reactive arthritis 1–3 . There are no specific clinical manifestations, which may be used to differentiate Giardia lamblia from other gastroenteritis.…”

Section: Figurementioning

confidence: 99%

See 1 more Smart Citation

Refractory diarrhea in a patient with rheumatoid arthritis

Taniguchi,

Yamamoto

2023

Int J of Rheum Dis

View full text Add to dashboard Cite

Section: Figurementioning

confidence: 99%

“…It often presents with flatulence, watery diarrhea, and extra-intestinal manifestation including reactive arthritis. [1][2][3] There are no specific clinical manifestations, which may be used to differentiate Giardia lamblia from other gastroenteritis. Ingesting cysts through contaminated water or person-to-person direct contact causes human infection.…”

mentioning

confidence: 99%

Refractory diarrhea in a patient with rheumatoid arthritis

Taniguchi,

Yamamoto

2023

Int J of Rheum Dis

View full text Add to dashboard Cite

Recent Advancements of Hyaluronic Acid Nanoscaffolds in Arthritis Management

Jana,

Ghosh,

Debnath

et al. 2024

ChemistrySelect

View full text Add to dashboard Cite

Arthritis is a significant health concern affecting over 528 million people globally, reducing quality of life. The chronic nature of arthritis, coupled with insufficient therapeutic effectiveness, recurrence, and adverse side effects, complicates its management. Hyaluronic acid (HA) has emerged as a promising solution due to its biocompatibility, non‐toxicity, and targeted drug delivery capabilities, being a key component of the cartilage extracellular matrix widely used in managing arthritis. HA's inherent viscoelastic property and ability to target CD44 have spurred interest in developing HA‐based systems for delivering drugs to manage arthritis. Hyaluronic acid nanoscaffolds (HA‐NSCfs) show improved outcomes over treatments, including enhanced drug uptake through receptor‐mediated targeting, prolonged retention in the synovium, reduced proinflammatory mediator expression, enhanced cartilage regeneration, reduced drug toxicity due to sustained release, and more cost‐effective treatments. This review highlights the rationale for using HA‐NSCfs for the management and advanced drug delivery systems in arthritis, emphasizing preclinical and clinical results. It discusses various solid‐lipid nanoparticles, hydroxyapatite nanoparticles, polyelectrolyte complexes, liposomes, bilosomes, drug‐polymer conjugates, hydrogels, inorganic nanoparticles, and polymer nanoparticles, etc reported for arthritis management. Additionally, the review identifies key challenges and offers suggestions to address them, ultimately highlighting the potential of HA‐NSCfs as a topical treatment for arthritis.

show abstract

Evaluation of clinical and paraclinical findings in patients with reactive arthritis caused by giardiasis: A systematic review

Cited by 2 publications

References 21 publications

Refractory diarrhea in a patient with rheumatoid arthritis

Refractory diarrhea in a patient with rheumatoid arthritis

Recent Advancements of Hyaluronic Acid Nanoscaffolds in Arthritis Management

Contact Info

Product

Resources

About